Vimab Group's earnings have been declining at an average annual rate of -32.6%, while the Professional Services industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 10.5% per year.
How Vimab Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OM:VIMAB Revenue, expenses and earnings (SEK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
318
-102
80
0
30 Sep 25
315
-91
86
0
30 Jun 25
297
-97
88
0
31 Mar 25
313
-90
94
0
31 Dec 24
325
-77
97
0
30 Sep 24
353
-39
94
0
30 Jun 24
376
-23
97
0
31 Mar 24
370
-12
89
0
31 Dec 23
342
-4
84
0
30 Sep 23
295
-14
77
0
30 Jun 23
255
-26
63
0
31 Mar 23
237
-27
61
0
31 Dec 22
227
-34
57
0
30 Sep 22
211
-28
55
0
31 Dec 21
206
-24
56
0
31 Dec 20
217
-46
45
0
Quality Earnings: VIMAB is currently unprofitable.
Growing Profit Margin: VIMAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIMAB is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare VIMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIMAB is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (-30.9%).
Return on Equity
High ROE: VIMAB has a negative Return on Equity (-281.51%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/08 05:47
End of Day Share Price
2026/05/08 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vimab Group AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.